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Abstract
The present study demonstrates at the molecular level that dextran derivatives carboxymethyl dextran benzylamine
 .  .CMDB and carboxymethyl dextran benzylamine sulfonate CMDBS , characterized by a statistical distribution of anionic
carboxylic groups, hydrophobic benzylamide units, andror sulfonate moieties, interact with HIV-1 LAI gp120 and V3
 .  .consensus clades B domain. Only limited interaction was observed with carboxy-methyl dextran CMD or dextran D
 .under the same conditions. CMDBS and CMDB 1 mM strongly inhibited HIV-1 infection of primary macrophages and
primary CD4q lymphocytes by macrophage-tropic and T lymphocyte-tropic strains, respectively, while D or CMD had
more limited effects on M-tropic infection of primary macrophages and exert no inhibitory effect on M- or T-tropic
 .infection of primary lymphocytes. CMDBS and CMDB 1 mM had limited but significant effect on oligomerized soluble
 .recombinant gp120 binding to primary macrophages while they clearly inhibit ) 50% such binding to primary
lymphocytes. In conclusion, the inhibitory effect of CMDB and the CMDBS, is observed for HIV M- and T-tropic strain
infections of primary lymphocytes and macrophages which indicates that these compounds interfere with steps of HIV
replicative cycle which neither depend on the virus nor on the cell. q 1997 Elsevier Science B.V.
1. Introduction
HIV-1 Env glycoprotein gp120 binding to CD4,
w xthe major virus receptor 1 , initiates a cascade of
events leading to virus–cell and cell–cell membrane
fusion. Different cellular cofactors glycolipids, pro-
.teins, glycoproteins have been assumed to be in-
) Corresponding author. Tel.: 33 1 48 38 77 52; fax: 33 1 48
38 77 77.
w xvolved in the latter events 2–4 but, in fact,
chemokine receptors CCR-5 and CXCR4 play then
 .the major role in the infection by macrophage M -
 .tropic or T lymphotropic T-tropic strains, respec-
w xtively 5 . The V3 region of gp120 appears to be
 .involved in such post-CD4-binding events by: i
binding to different cell surface membrane compo-
nents, including the recently identified virus corecep-
w x  .tors 5 ; ii interacting with CD4, possibly its
w x  .CDR3-like domain 6–8 ; and iii initiating thus Env
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conformational changes necessary for unmasking
w xgp41 fusogenic domain 9–11 . These possibilities
are not exclusive, since V3 is positively charged and
can interact with negatively charged cell surface
w xmolecules such as sulfated proteoglycans 12 . In this
context, sulfated polyanions, such as dextran sulfate
 .DS or heparin and other sulfated polysaccharides,
may inhibit HIV-1 infection of CD4q lymphoid cells
w x  .13–15 . For example, recombinant gp160 rgp160
specifically interacts with low molecular weight
 .  . w xMW DS 8 kDa, DS 8000 16 and inhibits HIV-1
infection of CD4q lymphoid cells by interfering with
w xvirus–cell interactions 17,18 . However, use of these
compounds for therapy is limited by their anti-
w xcoagulant activity 19–21 , and DS may enhance
rather than inhibit infection of primary macrophages
w xby M-tropic viruses 15 . Derivatized dextrans, in-
cluding a sulfonated molecule, also interact with
rgp160 and rgp41 with stronger affinities than ob-
w xserved for DS 8000 22 .
The present study was undertaken in order to
extend our previous findings and demonstrate at the
 .molecular level that dextran D derivatives devoid of
w xanticoagulant activity 23 and characterized by the
statistical distribution of anionic carboxylic groups,
hydrophobic benzylamide units, andror sulfonate
moieties, specifically interact with gp120 and its V3
domain, and inhibit HIV-1 infection of CD4q human
primary macrophages and lymphocytes by M-tropic
and T-tropic strains.
2. Materials and methods
2.1. Deri˝atized dextran
Water-soluble D derivatives were prepared as de-
w x scribed 23–25 from D, T40, MW: 49900 Phar-
.macia-LKB, St Quentin en Yvelines, France . The
chemical composition of the compounds was charac-
terized by acidimetric titration and elemental analy-
 .Fig. 1. Chemical representation of derivatized dextrans. Dextrans D were substituted by a sequential reaction in three steps in order to
 .  .  .  .obtain carboxymethyl groups CM , coupled with benzylamine B and finally sulfonation S of some aromatic rings or sulfation Su of
hydroxyl groups. Only the main substitution in the C2 position is depicted. The composition of three different CMDBS obtained by
varying the chemical conditions is shown in the table. Values are % of chemical groups per glucoside unit.
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 .sis. Carboxymethyl D CMD: 78% CM; 22% D was
synthesized from native D by substituting glucosyl
units with carboxymethyl groups. In a second step,
benzylamine was coupled with some carboxylic
groups to form benzylamide units CMDB: 35% B;
.59% CM; 6% D . Finally, benzylamide aromatic
rings were sulfonated. Three CMDBS 1, 2 and 3,
.corresponding to three preparations of the derivative
 .were investigated Fig. 1 . The anticoagulant activi-
ties of the three tested CMDBS were of 1.4, 0.8, and
3.5 IUrmg, respectively, for CMDBS 1, CMDBS 2,
CMDBS 3. The other dextran derivatives CMDB,
.  .CMD were as native dextran D devoid of anti-
coagulant activity. In comparison, the anticoagulant
activity of heparin is in the range of 170 IUrmg. DS
 .  .90% D; 10% S , MW: 32700 DS 32700 , was
w xsynthesized from T40 as described 23–25 .
 .The MW Table 1 of derivatized D was deter-
mined by high performance steric exclusion chro-
matography in 0.2 M NaCl, using a Licrospher Si 500
Diol column Merch–Clevenot, Nogent sur Marne,
.France calibrated with sulfonated polystyrene stan-
 .dards Polymer Laboratories, Montluc¸on, France .
 .In some experiments, DS 8000 8 kDa and D
 . 10000 10 kDa were purchased from Sigma St Louis,
.MO, USA .
2.2. Virus, rgp120 and V3 peptide
w xHIV-1 was a gift from Birgitta Asjo 26 , and¨Ba-L
HIV-1 was purchased from Diagnostics PasteurLAI
 .Marne la Coquette, France . Soluble rgp120 from
 . HIV-1 LAI )90% pure was from Intracell London,
. UK , and clades B V3 consensus peptide aa:
C T R P N N N T R K S IH IG P G R A F Y T T G E I -
. IGDIRQAHC was from Neosystem Strasbourg,
.France . Rgp120 and V3 were radiolabeled by the
w xiodogen method, as described 27 , or with iodobeads
 .Pierce, Oud-Beijerland, The Netherlands according
to the manufacturer’s instructions. The iodinated
molecule was separated from Na125I by filtration
 . through a Sephadex G-25 PD10 column Pharmacia,
.Uppsala, Sweden . Specific activity of labeled rgp120
and V3 was about 0.1 MBqrmg and 0.05 MBqrmg,
respectively.
( )2.3. Binding of rgp120 to sulfated D beads SDB
 .SDB Sigma were soaked for 24 h at 48C in
 .phosphate-buffered saline PBS , 0.1% sodium azide,
 .pH 7.4 PBS-azide . After three washes in PBS-azide,
SDB were suspended in an equal volume of 0.02 M
Tris, 0.15 M NaCl, 0.01 M CaCl , 0.05% bovine2
 .  .serum albumin BSA, Sigma Tris–Ca–BSA , pH
7.4. After one wash with 10 volumes Tris–Ca–BSA,
20 ml of matrix were incubated for 1 h at 378C with
y9 w125 x10 M I rgp120 in 60 ml buffer. Unbound glyco-
protein was removed by two washes of the matrix in
500 ml buffer. Solid phase-bound radioactivity was
 .counted in a g counter LKB, France . Results are
expressed as mean cpm of duplicates. Specificity of
the binding to the matrix was determined by incubat-
y9 w125 xing 10 M I rgp120 for 45 min at 378C with mM
concentrations of soluble DS 8000, DS 32700 or D
Table 1
w125 xInhibition of I rgp120 binding to SDB by derivatized D
Compound Bound rgp120 C Maximum inhibiting concentration Maximum % inhibition50
 .  .  .cpm mM mM
Buffer 9000 " 2280 y y y
 .D 10 kDa 9200 " 2757 y 266 0
a .D, T40 49.9 kDa 5950 " 2720 y 78 36 " 23
b .CMD 62.3 kDa 5510 " 2260 y 34 39 " 21
d .DS 32700 32.7 kDa 6080 " 1060 2 65 76 " 4
d .DS 8000 8 kDa 2860 " 1350 16 266 68 " 12
c .CMDB 61.7 kDa 4050 " 1850 34 34 51 " 21
c .CMDBS1 45 kDa 2368 " 1360 1.5 47 70 " 16
d .CMDBS2 57 kDa 2730 " 1450 2.5 37 57 " 28
Statistical significance of percent inhibitions relative to controls: a p - 0.05, b p - 0.02, c p - 0.01, d p - 0.001. Results are means " SD
of 6 independent experiments.
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10000, the latter used as negative control. Binding to
20 ml of SDB was then assayed. In parallel experi-
ments to determine the effect of derivatized D,
w125 xI rgp120 was preincubated with mM concentra-
tions of D, CMD, CMDB, CMDBS1 or CMDBS2,
which were kept in the mixture during the whole
assay.
2.4. Binding to the V3 peptide of the deri˝atized D
dotted onto nitrocellulose
CMDBS1, CMDBS2, CMDBS3, CMDB, CMD, D
10000 and Concanavalin A ConA; Sigma; 10 ml,
.10 mg were dotted onto nitrocellulose filters
 .Sartorius, Gottingen, FRG . After 30 min at 208C,¨
strips were saturated for 30 min at 378C with 2 ml
PBS, 5% BSA. Excess BSA was washed out with
 .PBS, 0.5% BSA, 0.2% Tween 20 Sigma , and strips
were incubated for 3–5 h at 378C with 0.5–
6 w125 x1 = 10 cpm of I V3. As control, labeled V3 was
preincubated for 1 h at 378C with a rabbit polyclonal
 .anti-V3 antibody 1 : 100; Neosystem, Paris, France
before incubation with the strips. After six washes
with the same buffer, strips were exposed at y208C
for 48 h or at y808C for 3 h.
2.5. Cells
 .Blood mononuclear cells PBMC of healthy vol-
unteers Seine–Saint–Denis or Pitie–Salpetriere´ ˆ `
.blood banks were obtained by Ficoll–Hypaque cen-
 .trifugation. Cells were either: i stimulated with
 .phytohemagglutinin PHA, DIFCO, Detroit, MI for
3 days in RPMI 1640, 50 mgrml penicillinrstrepto-
mycin, 2 mM L-glutamine, Gibco-BRL, Paisley,
. Scotland , 10% fetal calf serum FCS; Boheringer,
.  .  . 6Mannheim, FRG R10 ; or ii cultured at 2–5 = 10
cellsrml for 5 days in the same medium but with
10% heat-inactivated normal human pooled AB serum
 .  .Pitie–Salpetriere blood bank and 20% FCS 20% ,´ ˆ `
w xas described 28,29 . Nonadherent cells were then
removed by several washes in CarMg-free PBS.
Adherent cells were cultured in medium without AB
 .serum R20 for another 24–48 h before exposure to
HIV-1, or they were scrapped off with a rubber
 .policeman for analysis. Procedure ii yielded )90%
q  .CD14 monocyte-derived macrophages MDM with
)95% viability, which were viable for more than
one month.
[125 ]2.6. Binding of I rgp120 to the cells
 5 6.Cells 5 = 10 –1 = 10 were incubated for 2 h at
w125 x 48C or at 378C with 50 ml I rgp120 1–
5 y10 .4 = 10 cpm; 2–5 = 10 M in 80 ml RPMI, 0.05%
BSA, 0.05% azide, in order to avoid gp120 internal-
ization, or in Hank’s buffer supplemented with 0.05%
BSA, 0.05% azide, 10 mM CaCl in order, according2
w xto our previous data 30,31 to perform the experi-
ments with an oligomerized gp120. After two washes
 .700 g, 10 min, 48C , cell-bound radioactivity was
counted. The effect of D, DS 32700, CMD, CMDB,
CMDBS1 or CMDBS2 on rgp120 binding to the cells
w125 xwas analyzed as follows: I rgp120 was preincu-
bated for 1 h at 378C with different concentrations of
the products diluted in medium, and the mixture was
then incubated with cells as described above. It was
verified that cell viability was not modified in the
presence of Hank’s buffer supplemented with 10 mM
CaCl as assessed by trypan blue exclusion dye.2
2.7. HIV-1 infection of cells
 4HIV-1 2 = 10 cpm reverse transcriptase ac-Ba-L
. 5tivity was added for 18 h at 378C to 5 = 10 MDM
in 900 ml culture medium, 20% FCS, as described
w x28,29 ; unadsorbed virus was removed by washing,
and cells were further cultured. In parallel, virus was
pretreated for 45 min at 378C with the different D
 .derivatives, 5 mM Zidovudine AZT or 2.5 mgrml
 . anti-Leu3a monoclonal antibody mAb Becton dick-
.inson, Mountain View, CA , and the mixture was
added to 5 = 105 MDM for 18 h at 378C. Cells were
then cultured in the presence of the compounds at the
same concentrations than initially, after it was veri-
fied that this did not modify cell viability. Virus
production in supernatants collected twice a week
was assessed by measuring p24 by ELISA according
to the manufacturer’s instructions Diagnostics Pas-
.teur .
 .Peripheral blood lymphocytes PBL in R10 were
stimulated for 3 days with PHA. Then, 100 TCID50
 4of HIV-1 or HIV-1 2 = 10 cpm reverse tran-LAI BA-L
. scriptase activity in IL-2-supplemented 10 Urml;
.Boheringer R10 were incubated for 45 min at 378C
in R10, or with 1 mM of the different D derivatives or
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5 mM AZT in R10, and mixed thereafter with 5 = 105
PBL for 3 h at 378C. In parallel, PBL were incubated
for 30 min at 48C with 2.5 mgrml of anti-Leu3a
mAb. Cells were then washed twice in culture medium
 . 5400 g, 10 min , and cultured at 5 = 10 cellsrml.
Compounds were maintained at the initial concentra-
tion during the experiment. In some experiments,
viruses were directly co-incubated with the different
D derivatives and with the cells and washed out from
the culture medium. Supernatants were collected twice
a week to determine p24.
3. Result
3.1. Binding of rgp120 to deri˝atized D
We have shown that rgp120 specifically binds to
w xSDB 16,22 . Here, we confirm that preincubating
tetramerized rgp120, in the presence of 10 mM CaCl2
w x30,31 with DS 8000 or with DS 32700, inhibited
this binding, the C of the rgp120–DS 8000 interac-50
tion being 16 mM, that of the rgp120–DS 32700
being 2 mM; these data therefore demonstrate the
specificity of rgp120 binding to SDB Table 1, and
.data not shown . We show in addition that deriva-
tized D, CMDBS1, CMDBS2 and CMDB were also
 .efficient in this respect Table 1 . The affinity of
CMDBS1 and CMDBS2 interaction with rgp120,
with C of 1.5–2.5 mM, were 8–10-fold higher than50
for DS 8000, but of the same order of magnitude than
that noted in the presence of DS 32700. A lower
affinity, with a C of 34 mM, was noted for CMDB.50
D 10000 had no effect on gp120 binding to SDB
 .while D T40 or CMD had limited but significant
effects. This indicates that the D structure by itself or
anionic CMD only slightly interact with rgp120.
3.2. Interaction of D deri˝ati˝es with the clades B V3
consensus peptide
Clades B V3 consensus peptide interacted with
CMDB, CMDBS1, CMDBS2 and CMDBS3, but not
with CMD nor with D 10000 or ConA dotted onto
 .nitrocellulose Fig. 2 ; binding of V3 to CMDB or to
CMDBS compounds was significantly inhibited by
 .anti-V3 antibodies data not shown , which indicates
its specificity.
3.3. rgp120 binding to MDM and PBL
No inhibition of rgp120 binding to MDM or to
PBL was observed, in RPMI medium at q48C, in the
presence of the tested compounds: D, DS 32700,
 .CMD, CMDB and CMDBS 1 and 2 ; mAb anti-
Leu3a, used as control, induced 2-fold inhibition of
rgp120 binding to PBL but had no effect on the
 .binding to MDM data not shown , in agreement with
w xprevious findings 28,29,32 . However, when the ex-
periments were performed at 378C, in Hank’s buffer
supplemented with 10 mM CaCl , in order to ap-2
proach the effects of the various dextran derivatives
w xon oligomerized gp120 binding to the cells 30,31 ,
6 mM CMD, CMDBS1 and CMDBS2 significantly
 .and strongly )50% inhibited rgp120 binding to
MDM; however, 1 mM of these compounds had sig-
nificant but more limited effects mean % of inhibi-
.tion s 29–30% . In the same conditions, T40, DS
 .  .32700 or CMD had no effect Table 2 . Neverthe-
less, CMDB, CMDBS1 and CMDBS2, at 1 mM con-
centrations, significantly and rather strongly inhibited
rgp120 binding to PBL mean percentages of inhibi-
.  .tion: 51–58% ; DS 32700 had more limited but
significant effect; on the contrary, T40 or CMD had
no effect.
 .Fig. 2. Interactions of derivatized D 10 mg with the V3 consensus peptide. 1: ConA; 2: CMDB; 3: CMDBS1; 4: CMDBS2; 5:
CMDBS3; 6: CMD; 7: D 10000. Data are from one out of three experiments.
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Table 2
125  .I rgp120 binding to monocyte-derived macrophages MDM
 .and peripheral blood lymphocytes PBL in 10 mM CaCl sup-2
plemented medium
Bound radioactivity % inhibition
 .cpm
MDM
Control 25500" 5350 y
 .T40 14 mM 24800" 3150 y
 .DS 47mM 22680" 6500 y
 .CMD 6 mM 24300" 4900 y
a a .CMDB 6 mM 10230" 5800 64 " 12
b b .CMDB 1mM 17700" 5900 29 " 7
c a .CMDBS1 8 mM 7634" 3900 71 " 9
c c .CMDBS1 1mM 17340" 4360 23 " 14
a a .CMDBS2 6 mM 6780" 4300 75 " 100
c c .CMDBS2 1mM 15526" 4110 30 " 22
PBL
Control 5900" 3600 y
 .T40 1.8 mM 4400" 2370 29 " 29
c c .DS 1mM 2745" 1600 44 " 17
 .CMD 1mM 3500" 1700 23 " 23
c c .CMDB 1mM 2170" 695 51 " 20
c c .CMDBS1 1mM 2220" 890 55 " 14
b b .CMDBS2 1mM 2250" 990 58 " 8
Results are means" S.D. of 3–7 independent experiments. Sta-
tistical significance of the differences relative to control as
determined by the paired Student’s t-test.
a p - 0.01; b p - 0.02.; c p - 0.05.
3.4. Effect of dextran deri˝ati˝es on HIV-1 infection
of MDM and PBL
We then tested the effect of the three CMDBS
preparations, CMDB, CMD, D and DS 32700 on
HIV-1 infection of MDM. The compounds wereBa-L
preincubated with the virus before addition to the
cells, and were then kept at initial concentrations for
the whole culture. AZT or mAb anti-Leu3a were used
as positive control of inhibition. The CMDBS prepa-
rations and CMDB strongly inhibited in a dose-de-
pendent manner HIV-1 infection p24 levels rang-Ba-L
ing from 180 to 2200 pgrml on day 18 post-infection
with 1 mM of compound, relative to 9300–
.11200 pgrml without compound , while CMD, DS
 .32700 and D 50 mgrml had more limited effects
  .  ..Fig. 3 a , b .
To examine whether CMDB and CMDBS could
protect other primary cells from infection with the
same as well as with another virus strain, we ana-
lyzed their effect on HIV-1 and HIV-1 infec-LAI Ba-L
tion of primary PBL, using mAb anti-Leu3a as con-
trol as previously. The CMDBS and CMDB also
strongly inhibited HIV-1 as well as HIV-1LAI Ba-L
infection of PBL, whereas no inhibition was observed
in the presence of CMD, DS 32700 or D. Similar
results were observed whether virus was pre-treated
or not with the CMDBS. However, when CMDB or
CMDBS1 were washed out from the culture medium,
p24 production returned to the levels observed for the
  .  ..control Fig. 4 a – c . Taken together, these results
demonstrate that CMDB and CMDBS compounds
inhibit M-tropic and T-tropic HIV infections of pri-
Fig. 3. Effect of derivatized D on HIV-1 infection of MDM.Ba-L
 .  .a Infection was conducted in the absence Tq or in the
presence of CMDBS1, CMDBS2, CMDB, CMD, D, DS 32700
 .  .  .each at 1mM or of AZT 5mM . b Effect on infection of
 .different amounts of CMDBS3 0.01, 0.1 and 1mM or of mAb
 .  .  .anti-Leu3a 2.5mgrml . Data in a and b are from two differ-
ent experiments out of four.
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mary macrophages and lymphocytes and indicate that
these compounds may interfere with post-binding
events.
4. Discussion
Several soluble derivatized D with different per-
centages of carboxymethyl, benzylamide and sul-
fonatersulfate groups were evaluated for possible
inhibitory effects on HIV-1 infection of primary
MDM and PBL by M-tropic and T-tropic HIV-1
strains, respectively. We first observed, in accordance
with our previous results, specific interactions be-
tween soluble tetramerized rgp120 in the presence of
10 mM CaCl and SDB inasmuch as these interac-2
tions were inhibited by DS 8000 and by DS 32700.
We also observed specific interactions between
rgp120 and two CMDBS compounds CMDBS1 and
. 2 at the molecular level, with C values 1.5–50
.2.5 mM similar to those of rgp160 interacting with
w xCMDBS3 22 .
The affinity of CMDB binding to rgp120 C s50
.34 mM noted here was lower than that noted previ-
 . w xously using rgp160 C s 2 mM 22 , which sug-50
gests gp41 involvement in this interaction. In addi-
tion, no interaction occurred between rgp120 and D
10000, which indicates specificity of the interactions,
while limited interactions occurred in the presence of
D, T40 or CMD with maximum % of inhibition of
.gp120 binding to SDB of 36–39% . Furthermore,
specific interactions were also observed, here, be-
tween a peptide mimicking the clades B consensus
V3 loop of gp120 and CMDB or CMDBS, but not
CMD or D.
The CMDBS and CMDB also strongly inhibited
HIV infection of MDM by a M-tropic strain and of
PBL by M- and T-tropic strain. These results indicate
that the inhibitory effects of the compounds do not
depend on the virus strain nor on the target cells. This
Fig. 4. Effect of derivatized D on HIV-1 or of HIV-1LAI Ba-L
 .infection of PBL. Infection was conducted in the absence Tq
or in the presence of CMDBS1, CMDBS2, CMDB, CMD, D,
 .DS32700 each at 1mM which were preincubated with the virus
and maintained at initial concentration in the culture medium, or
 .  .  .of mAb anti-Leu3a 2.5mgrml . a HIV-1 or b HIV-1LAI Ba-L
 .infection of PBL. c HIV-1 infection of PBL in the presenceBa-L
of CMDBS1, CMDBS2, CMDB which were not preincubated
with the virus but only coincubated with the virus and with the
PBL. CMDB and CMDBS1 were washed out from the culture
medium. Data are from one out of two experiments.
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means that the inhibitory effect of these compounds
does not depend on the HIV-1 co-receptors used,
CXCR4 during HIV-1 infection of PBL or CCR5LAI
w xduring HIV-1 infection of PBL or MDM 5 . AsBA-L
other HIV-1 subtypes, C, D, E or O also use CXCR4
w xandror CCR5 33 , an inhibitory effect of their infec-
tion by the presently tested compound cannot be
excluded. Our results extend findings by Neyts et al.
w x34 using different experimental conditions, that
CMDB and the CMDBS inhibited HIV-1-induced
cytopathicity for lymphoid MT4 cells, whereas D or
CMD had no activity. Our present results, obtained
on primary lymphocytes, which report that D, T40
and CMD are devoid of effects on T-tropic infection
of primary lymphocytes are therefore in agreement
w xwith those observed by Neyts et al. 34 on a lymphoıd¨
cell line. It is to note that D, T40 or CMD which are
devoid of any inhibitory effect on HIV-1 infection of
primary lymphocytes and exert limited effect on
HIV-1 infection of primary macrophages are able,
according to the present data, to slightly interact with
rgp120. In this respect, it must be considered that
some high affinity gp120 ligands, such as galactosyl-
ceramide or sulfatide, have no role on HIV infection
w xof primary cells 29 . On the other hand, enhance-
ment of HIV infection of primary cells from some
blood donors has been described in the presence of
w xDS 15 ; therefore, the purpose of the present study
was not to investigate again its effects on HIV infec-
tion, but rather to analyze those of other dextran
derivatives, especially CMDB and CMDBS on T- or
M-tropic infection of primary cells. Indeed, in the
present study, DS 32700, characterized by only 10%
sulfated groups, had some inhibitory effects on HIV-1
infection of MDM, while it was devoid of effect on
M- or T-tropic HIV-1 infection of PBL; this may be
related to its MW, negative charge, low amount of
sulfated groups andror the blood donor target cells
w xused. Indeed it has been suggested 15,35 that there
is a critical MW required for DS anti-HIV-1 activity,
that interactions of these compounds with the cells
has also to be considered and that different results,
w xaccording to the blood donors can be observed 15 .
Here, CMDB and the CMDBS, at 1 mM concentra-
tion, only slightly, but significantly, inhibit oligomeric
rgp120 binding to MDM, which rules out that they
mainly act on primary gp120 binding to MDM and
rather suggest that they interfere with some of other
steps occurring during HIV M-tropic viral cycle.
However, at 1 mM concentration, these compounds
inhibit by 51–58% oligomerized gp120 binding to
PBL which strongly indicates that during T-tropic
infection of primary lymphocytes, CMDB and
CMDBS interfere with some HIV env binding steps
to the cells. In addition, we report, here, that CMDB
and CMDBS, but not CMD or D 10000, specifically
interact with clades B V3 consensus domain which
indicates that these compounds may interfere with
post-binding events necessary for viral entry. Indeed,
strong inhibitory effects of CMDB or CMDBS on
HIV infection were only observed when these com-
pounds were maintained in the culture medium at
initial concentration, which further strongly suggests
that they interfere with some post-binding events.
That D and CMD had no or limited effect on
HIV-1 infection of MDM and PBL, as compared to
the inhibitory effect of CMDB and the CMDBS,
indicates that compounds that contain sufficiently
high combined percentages of benzylamide and ben-
zylamide sulfonate groups elicit anti-HIV-1 activity.
Of note, a prototype compound T1C4E5-tribenzyl-
.CD4 from the CDR3 region of CD4 inhibited at mM
concentration HIV-1-induced cell fusion and infec-
w xtion of transformed T lymphoid cells 36 . These
results suggest that the cyclic chemical presentation
 .of these compounds benzyl is necessary to observe
any inhibition of infection.
In conclusion, the inhibitory effect of CMDB and
the CMDBS which are devoid of toxicity and anti-
w xcoagulant activity when injected to animals 37,38 , is
observed for HIV M- and T-tropic strain infection of
primary lymphocytes and macrophages which indi-
cates that they interfere with steps of HIV replicative
cycle which do not depend on the virus nor on the
cell. Their use as anti-HIV therapeutic agents can
therefore be proposed.
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